Quick Answer
DiaMedica Therapeutics Inc. reported Operating Income of -$34.40 million for fiscal year 2025.
DiaMedica Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$34.40M | -28.9% |
| 2024 | -$26.68M | -25.5% |
| 2023 | -$21.27M | -51.9% |
| 2022 | -$14.00M | -2.6% |
| 2021 | -$13.65M | -7.5% |
| 2020 | -$12.70M | -9.5% |
| 2019 | -$11.59M | -71.5% |
| 2018 | -$6.76M | -49.6% |
| 2017 | -$4.52M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$9.03M | -31.2% | -12.8% |
| June 30, 2025 | -$8.01M | -42.0% | +1.7% |
| March 31, 2025 | -$8.14M | -41.9% | -18.3% |
| September 30, 2024 | -$6.88M | -33.5% | -22.1% |
| June 30, 2024 | -$5.64M | -18.9% | +1.8% |
| March 31, 2024 | -$5.74M | -4.0% | -11.3% |
| September 30, 2023 | -$5.16M | -64.9% | -8.8% |
| June 30, 2023 | -$4.74M | -40.9% | +14.1% |
- DiaMedica Therapeutics Inc. showed a decrease of -28.9% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, DiaMedica Therapeutics Inc.’s operating income has declined by 661.2% (from -$4.52 million to -$34.40 million).
- The most recent figure is from DiaMedica Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: